279 related articles for article (PubMed ID: 14732596)
21. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
Purdon SE; Woodward N; Lindborg SR; Stip E
Psychopharmacology (Berl); 2003 Sep; 169(3-4):390-7. PubMed ID: 12827347
[TBL] [Abstract][Full Text] [Related]
22. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
Edgell ET; Andersen SW; Johnstone BM; Dulisse B; Revicki D; Breier A
Pharmacoeconomics; 2000 Dec; 18(6):567-79. PubMed ID: 11227395
[TBL] [Abstract][Full Text] [Related]
24. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report.
Lerner V; Chudakova B; Kravets S; Polyakova I
Clin Neuropharmacol; 2000; 23(5):284-6. PubMed ID: 11154098
[TBL] [Abstract][Full Text] [Related]
25. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Meyer JM
J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
[TBL] [Abstract][Full Text] [Related]
26. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
[TBL] [Abstract][Full Text] [Related]
27. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
28. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.
Zhou Y; Li G; Li D; Cui H; Ning Y
J Psychopharmacol; 2018 May; 32(5):524-532. PubMed ID: 29493377
[TBL] [Abstract][Full Text] [Related]
29. The effects of risperidone and olanzapine on the indications for clozapine.
Ganguli R; Brar JS
Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
[TBL] [Abstract][Full Text] [Related]
30. Olanzapine for schizophrenia.
Duggan L; Fenton M; Dardennes RM; El-Dosoky A; Indran S
Cochrane Database Syst Rev; 2000; (2):CD001359. PubMed ID: 10796640
[TBL] [Abstract][Full Text] [Related]
31. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.
Ho BC; Miller D; Nopoulos P; Andreasen NC
J Clin Psychiatry; 1999 Oct; 60(10):658-63. PubMed ID: 10549681
[TBL] [Abstract][Full Text] [Related]
32. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
33. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Glick ID; Berg PH
Int Clin Psychopharmacol; 2002 Mar; 17(2):65-8. PubMed ID: 11890188
[TBL] [Abstract][Full Text] [Related]
34. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
Harvey PD; Napolitano JA; Mao L; Gharabawi G
Int J Geriatr Psychiatry; 2003 Sep; 18(9):820-9. PubMed ID: 12949850
[TBL] [Abstract][Full Text] [Related]
35. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Purdon SE; Jones BD; Stip E; Labelle A; Addington D; David SR; Breier A; Tollefson GD
Arch Gen Psychiatry; 2000 Mar; 57(3):249-58. PubMed ID: 10711911
[TBL] [Abstract][Full Text] [Related]
36. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness of antipsychotic drugs.
Messori A
Am J Psychiatry; 2003 Mar; 160(3):591-2; author reply 592-3. PubMed ID: 12611854
[No Abstract] [Full Text] [Related]
38. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.
Harvey PD; Green MF; McGurk SR; Meltzer HY
Psychopharmacology (Berl); 2003 Sep; 169(3-4):404-11. PubMed ID: 12590356
[TBL] [Abstract][Full Text] [Related]
39. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.
Fontaine CS; Hynan LS; Koch K; Martin-Cook K; Svetlik D; Weiner MF
J Clin Psychiatry; 2003 Jun; 64(6):726-30. PubMed ID: 12823090
[TBL] [Abstract][Full Text] [Related]
40. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
Rabinowitz J; Lichtenberg P; Kaplan Z; Mark M; Nahon D; Davidson M
Am J Psychiatry; 2001 Feb; 158(2):266-9. PubMed ID: 11156809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]